Mesoblast has acquired an exclusive worldwide license to a patented chimeric antigen receptor technology platform to enhance mesenchymal lineage stromal cell products for inflammatory and autoimmune diseases, according to an April 14, 2026, announcement.
Mesoblast Acquires Precision-Enhanced CAR Platform for Stromal Cell Products
In a strategic move to boost the potency of its cell therapies, Mesoblast Limited acquired an exclusive worldwide license to a patented chimeric antigen receptor technology platform. The technology is designed for the precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell products. By incorporating engineered CAR constructs into mesenchymal stromal cells, the company aims to enhance target specificity, augment immunomodulation, and improve tissue regeneration in inflammatory conditions.
Foundational work on the platform was developed by investigators at Mayo Clinic and published in Nature Biomedical Engineering. These researchers identified various CAR-MSCs capable of enhanced tissue-specific targeting in inflammatory and autoimmune diseases, including inflamed bowel tissue. This provides an immediate opportunity to generate products with greater potency for ulcerative colitis or Crohn’s disease.
“This innovative genetic modification technology fits well with our strategy to extend our market leadership by creating products with even greater efficacy and new target indications.”
Silviu Itescu, Chief Executive of Mesoblast
Beyond gastrointestinal applications, Mesoblast plans to utilize CAR-MSCs engineered to express CD19 on their surface. The goal is to induce remission in lupus nephritis and other B cell autoimmune diseases where durable immunomodulation is highly desirable. Mayo Clinic will provide in-kind support for GMP manufacturing activities. The acquisition itself was completed through the issuance of ASX ordinary shares.
Expanding Beyond Oncology Into Autoimmune and Chronic Conditions
While chimeric antigen receptor T-cell therapy originally emerged for cancer, clinical exploration has expanded. A review published in Signal Transduction and Targeted Therapy examines how these engineered cells are being adapted to target persistent disease-driving cells across a wide array of non-cancer conditions, including autoimmune diseases, persistent infections, fibrotic diseases, hemophilia, transplantation, and cellular senescence.
In autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and inflammatory muscle diseases, CAR-T cells are explored as a method to remove autoreactive B cells and other cells sustaining harmful immune responses. Unlike conventional treatments that rely on continuous immune suppression, CAR-T therapy may help reorganize the immune system after targeted depletion of disease-driving cells.
Researchers utilize flexible antigen targets depending on the specific disease pathway. Broad B-cell populations can be addressed using CD19, CD20, and CD22, while BCMA, CD38, and CD138 target antibody-producing plasma cells. Furthermore, antigen-specific approaches focus more precisely on disease-associated immune cells.
CAR Construct Architecture and Cancer Treatment
The CAR protein is composed of an external recognition region and an internal signaling region. The internal signaling region typically includes the signaling molecules and signaling modules required to activate T cells.
Regulatory Perspectives and Safety Considerations for Chronic Patients
Safety requirements remain paramount, particularly when evaluating therapies for chronic autoimmune conditions where patients may otherwise live for many years. Because these therapies introduce potent biological mechanisms into the human body, newer approaches emphasize controlled activation, temporary activity, and tissue-specific targeting to minimize unwanted immune effects.
“These engineered cells represent the first clinically viable modality capable of executing complex, conditional biological programs within the human body.”
Saurabh Upadhyay and colleagues, via Medindia
Looking Ahead: Commercial Scale and Clinical Development Pathways
Manufacturing and scalability present ongoing challenges for widespread clinical adoption. As early- and late-phase clinical trials progress, the trajectory of engineered cell therapies points toward increasingly precise immune reprogramming that could alter the management of chronic disease.